MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Example Regimen Order: PHD (Jane Smith, First-Line Metastatic HER2+)

Raw json | Download

{
  "resourceType" : "RequestGroup",
  "id" : "PHDRegimenOrder",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/anticancer-regimen-requestgroup"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: RequestGroup PHDRegimenOrder</b></p><a name=\"PHDRegimenOrder\"> </a><a name=\"hcPHDRegimenOrder\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-anticancer-regimen-requestgroup.html\">Anti-Cancer Regimen RequestGroup</a></p></div><p><b>Request Category</b>: <span title=\"Codes:{http://snomed.info/sct 363676003}\">Palliative intent</span></p><p><b>Request Category</b>: <span title=\"Codes:{http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs 1L}\">First-line</span></p><p><b>instantiatesCanonical</b>: <a href=\"PlanDefinition-RegimenPHD.html\">PHD: Pertuzumab + Trastuzumab + Docetaxel — Metastatic HER2+ Breast Cancer</a></p><p><b>status</b>: Draft</p><p><b>intent</b>: Order</p><p><b>subject</b>: <a href=\"Patient-MOPAPatientExample.html\">Jane Smith (official) Female, DoB: 1968-04-15 ( http://hospital.example.org/patients#MRN-78432)</a></p><blockquote><p><b>action</b></p><blockquote><p><b>id</b></p>pertuzumab-phd-action</blockquote><p><b>title</b>: Pertuzumab IV day 1 q21d</p><p><b>timing</b>: Once per 21 days</p><p><b>resource</b>: <a href=\"MedicationRequest-PertuzumabMedRequestPHD.html\">MedicationRequest: status = draft; intent = order; medication[x] = pertuzumab</a></p></blockquote><blockquote><p><b>action</b></p><blockquote><p><b>id</b></p>trastuzumab-phd-action</blockquote><p><b>title</b>: Trastuzumab IV day 1 q21d</p><p><b>timing</b>: Once per 21 days</p><p><b>resource</b>: <a href=\"MedicationRequest-TrastuzumabMedRequestPHD.html\">MedicationRequest: status = draft; intent = order; medication[x] = trastuzumab</a></p></blockquote><blockquote><p><b>action</b></p><blockquote><p><b>id</b></p>docetaxel-phd-action</blockquote><p><b>title</b>: Docetaxel 75 mg/m² IV day 1 q21d</p><p><b>timing</b>: Once per 21 days</p><p><b>resource</b>: <a href=\"MedicationRequest-DocetaxelMedRequestPHD.html\">MedicationRequest: status = draft; intent = order; medication[x] = docetaxel</a></p></blockquote></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/us/davinci-crd/StructureDefinition/ext-request-category",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "363676003",
            "display" : "Palliative intent"
          }
        ]
      }
    },
    {
      "url" : "http://hl7.org/fhir/us/davinci-crd/StructureDefinition/ext-request-category",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs",
            "code" : "1L",
            "display" : "First-line"
          }
        ]
      }
    }
  ],
  "instantiatesCanonical" : [
    🔗 "http://hl7.org/fhir/us/codex-mopa/PlanDefinition/RegimenPHD"
  ],
  "status" : "draft",
  "intent" : "order",
  "subject" : {
    🔗 "reference" : "Patient/MOPAPatientExample"
  },
  "action" : [
    {
      "id" : "pertuzumab-phd-action",
      "title" : "Pertuzumab IV day 1 q21d",
      "timingTiming" : {
        "extension" : [
          {
            "extension" : [
              {
                "url" : "day",
                "valueInteger" : 1
              }
            ],
            "url" : "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/regimen-days-of-cycle"
          }
        ],
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      },
      "resource" : {
        🔗 "reference" : "MedicationRequest/PertuzumabMedRequestPHD"
      }
    },
    {
      "id" : "trastuzumab-phd-action",
      "title" : "Trastuzumab IV day 1 q21d",
      "timingTiming" : {
        "extension" : [
          {
            "extension" : [
              {
                "url" : "day",
                "valueInteger" : 1
              }
            ],
            "url" : "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/regimen-days-of-cycle"
          }
        ],
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      },
      "resource" : {
        🔗 "reference" : "MedicationRequest/TrastuzumabMedRequestPHD"
      }
    },
    {
      "id" : "docetaxel-phd-action",
      "title" : "Docetaxel 75 mg/m² IV day 1 q21d",
      "timingTiming" : {
        "extension" : [
          {
            "extension" : [
              {
                "url" : "day",
                "valueInteger" : 1
              }
            ],
            "url" : "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/regimen-days-of-cycle"
          }
        ],
        "repeat" : {
          "period" : 21,
          "periodUnit" : "d"
        }
      },
      "resource" : {
        🔗 "reference" : "MedicationRequest/DocetaxelMedRequestPHD"
      }
    }
  ]
}